We are live on ! Find out more
EP

Eversept Partners Portfolio holdings

AUM $1.93B Turnover 41.06%
1-Year Est. Return 160.8%
This Fund
S&P 500
This Quarter Est. Return
+20.72%
1 Year Est. Return
+160.8%
3 Year Est. Return
+321.09%
5 Year Est. Return
+420.29%
10 Year Est. Return
–
AUM
$215M
AUM Growth
+$41.5M
Cap. Flow
+$31.8M
Cap. Flow %
14.78%
Top 10 Hldgs %
55.52%
Holding
68
New
22
Increased
11
Reduced
19
Closed
11
Avg Time Held Equity + Options
0.2 years
Top 10 Avg Time Held Equity + Options
0.1 years
Top 20 Avg Time Held Equity + Options
0.2 years
Avg Time Held Equity only
0.2 years
Top 10 Avg Time Held Equity only
0.1 years
Top 20 Avg Time Held Equity only
0.2 years

Top Buys

Rank Stock Value
1
QCP
Quality Care Properties, Inc.
QCP
+$11.7M
2
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$10.2M
3
ARNA
Arena Pharmaceuticals Inc
ARNA
+$8.59M
4
GSK icon
GSK
GSK
+$8.44M
5
AVXS
AveXis, Inc. Common Stock
AVXS
+$6.04M

Top Sells

Rank Stock Value
1
ARRY icon
Array Biopharma Inc
ARRY
+$14.1M
2
EHTH icon
eHealth
EHTH
+$4.18M
3
ALXN
Alexion Pharmaceuticals
ALXN
+$4.01M
4
EVHC
Envision Healthcare Holdings Inc
EVHC
+$2.62M
5
PBYI icon
Puma Biotechnology
PBYI
+$2.38M

Sector Composition

Rank Sector Weight
1 Healthcare 75.31%
2 Real Estate 9.99%
3 Miscellaneous 7.87%
4 Industrials 6.33%
5 Financials 0.5%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
QCP
1
DELISTED
Quality Care Properties, Inc.
QCP
$20M 9.3%
1,030,661
+782,015
+315% +$11.7M
2017 Q4
1 quarter
SPY icon
2
PUT
State Street SPDR S&P 500 ETF Trust
SPY
$814B
$15.8M 7.33%
60,000
-30,000
-33% -$8.19M
2017 Q4
1 quarter
RCM icon
3
DELISTED
R1 RCM Inc. Common Stock
RCM
$13.6M 6.33%
1,909,887
+268,009
+16% +$1.51M
2017 Q4
1 quarter
RDUS icon
4
DELISTED
Radius Health, Inc.
RDUS
$12M 5.57%
333,738
+139,237
+72% +$5.03M
2017 Q4
1 quarter
AERI
5
DELISTED
Aerie Pharmaceuticals
AERI
$11.4M 5.31%
210,778
-30,702
-13% -$1.72M
2017 Q4
1 quarter
ABLX
6
DELISTED
Ablynx NV
ABLX
$9.92M 4.61%
181,891
+81,012
+80% +$4.01M
2017 Q4
1 quarter
AVXS
7
DELISTED
AveXis, Inc. Common Stock
AVXS
$9.66M 4.49%
78,201
+50,831
+186% +$6.04M
2017 Q4
1 quarter
ALNY icon
8
Alnylam Pharmaceuticals
ALNY
$31.6B
$9.4M 4.36%
+78,893
New +$10.2M
2018 Q1
0 quarters
GSK icon
9
GSK
GSK
$99.4B
$8.95M 4.16%
+181,267
New +$8.44M
2018 Q1
0 quarters
ARNA
10
DELISTED
Arena Pharmaceuticals Inc
ARNA
$8.72M 4.05%
+220,788
New +$8.59M
2018 Q1
0 quarters
ENSG icon
11
The Ensign Group
ENSG
$10.4B
$8.59M 3.99%
348,384
-6,254
-2% -$149K
2017 Q4
1 quarter
ZGNX
12
DELISTED
Zogenix, Inc.
ZGNX
$8.19M 3.8%
204,546
-13,832
-6% -$549K
2017 Q4
1 quarter
VRTX icon
13
Vertex Pharmaceuticals
VRTX
$129B
$7.31M 3.39%
44,822
-13,300
-23% -$2.17M
2017 Q4
1 quarter
ARRY icon
14
DELISTED
Array Biopharma Inc
ARRY
$5.84M 2.71%
357,727
-880,076
-71% -$14.1M
2017 Q4
1 quarter
SNY icon
15
Sanofi
SNY
$96.6B
$5.53M 2.57%
137,972
-50,000
-27% -$2.08M
2017 Q4
1 quarter
NVRO icon
16
DELISTED
NEVRO CORP.
NVRO
$5.27M 2.45%
60,850
-4,000
-6% -$323K
2017 Q4
1 quarter
TLGT
17
DELISTED
Teligent, Inc
TLGT
$5.21M 2.42%
155,038
-11,051
-7% -$352K
2017 Q4
1 quarter
SAGE icon
18
DELISTED
Sage Therapeutics
SAGE
$3.87M 1.8%
+24,000
New +$4.07M
2018 Q1
0 quarters
BMRN icon
19
BioMarin Pharmaceuticals
BMRN
$10.7B
$3.73M 1.73%
46,000
+300
+0.7% +$25.7K
2017 Q4
1 quarter
TSRO
20
DELISTED
TESARO, Inc.
TSRO
$2.94M 1.37%
51,523
-34,217
-40% -$2.2M
2017 Q4
1 quarter
ARGX icon
21
argenx
ARGX
$51.9B
$2.88M 1.34%
35,784
+8,124
+29% +$614K
2017 Q4
1 quarter
ABT icon
22
Abbott
ABT
$182B
$2.87M 1.33%
+47,900
New +$2.89M
2018 Q1
0 quarters
TGTX icon
23
TG Therapeutics
TGTX
$8.39B
$2.13M 0.99%
+150,000
New +$1.92M
2018 Q1
0 quarters
ABMD
24
DELISTED
Abiomed Inc
ABMD
$2.06M 0.96%
7,094
-1,500
-17% -$380K
2017 Q4
1 quarter
MYOK
25
DELISTED
MyoKardia, Inc. Common Stock
MYOK
$2.05M 0.95%
42,000
-8,000
-16% -$416K
2017 Q4
1 quarter
1
2 3

Similar funds

SWM
Segment Wealth Management Houston, Texas $1.93B AUM 29.24% 1-Year Est. Return
RIA
Regal Investment Advisors Kentwood, Michigan $1.92B AUM 23.13% 1-Year Est. Return
SI
Standard Investments New York $1.93B AUM 6.23% 1-Year Est. Return
SG
Sourcerock Group Denver, Colorado $1.92B AUM 45.54% 1-Year Est. Return
DCP
Distillate Capital Partners Chicago, Illinois $1.92B AUM 5.31% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
MFM
MHR Fund Management New York $1.92B AUM 119.57% 1-Year Est. Return
FWP
FAS Wealth Partners Leawood, Kansas $1.92B AUM 26.86% 1-Year Est. Return

Eversept Partners's Q1 2018 Portfolio in Review

As of Q1 2018, Eversept Partners held 68 positions worth $215M, up 24% from $174M the previous quarter. Its ten largest holdings account for 56% of the portfolio.

Eversept Partners deployed $31.8M of net new capital in Q1 2018, opening 22 new positions and adding to 11 existing holdings. Its largest new stake was Alnylam Pharmaceuticals: 78,893 shares worth $9.4M.

By sector, the portfolio is most concentrated in Healthcare at 75% of assets, down from 75% a quarter earlier, followed by Real Estate and Miscellaneous.

On the sell side, the largest reduction was Array Biopharma Inc, an estimated $14.1M trimmed.

  • Eversept Partners's largest Q1 2018 buy was Alnylam Pharmaceuticals: 78,893 shares worth $9.4M.
  • Eversept Partners added most to Quality Care Properties, Inc. in Q1 2018, an estimated $11.7M increase.
  • Eversept Partners's biggest Q1 2018 reduction was Array Biopharma Inc, cutting an estimated $14.1M.
  • Eversept Partners fully exited Alexion Pharmaceuticals in Q1 2018, selling an estimated $4.01M.
  • Eversept Partners's ten largest holdings make up 56% of its $215M portfolio in Q1 2018.
  • Eversept Partners opened 22 new positions and closed 11 in Q1 2018.
  • Eversept Partners's portfolio value rose 24% quarter-over-quarter to $215M.

Based on Eversept Partners's 13F filing for Q1 2018, filed 14 May 2018.